FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma

PRESS RELEASE FDA Approval

06/06/2022

Novartis AG

Basel, May 28, 2022 — Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah® (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. In accordance with the Accelerated Approval Program, continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Kymriah is now FDA approved in three indications and remains the only CAR-T cell therapy approved in both adult and pediatric settings.

Related News

Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma

Basel, August 24, 2021 — Novartis today announced an update on the Phase III BELINDA study investigating Kymriah® (tisagenlecleucel) in aggressive B-c...

13/09/2021

PRESS RELEASE Research Findings

DAIICHI SANKYO AUTHORIZES THE FIRST YESCARTA® (AXICABTAGENE CILOLEUCEL) CAR T-CELL THERAPY TREATMENT SITE IN JAPAN

Santa Monica, Calif. and Tokyo – December 16, 2021 – Kite, a Gilead Company, and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today ann...

23/12/2021

PRESS RELEASE Corporate Announcements

ASEC Frontier (Thailand) Co., Ltd

Address : 1 Empire Tower, Unit 1509,1710

15th,17th floor South Sathorn road Yannawa

Sathorn Bangkok, Thailand 10120

Tel : +662-118-0873

Email : info@medical-leaders-thailand.com

Website : www.asec-frontier.com

 

Contact Us